News

Kytopen announces expansion of its partnership program into Europe with its agreement with T-CURX...
Successful engineering of macrophages is of critical importance for next-generation...
Charles River generated best-in-class data with Kytopen’s Flowfect™ technology in comparative...
Kytopen awarded competitive phase II SBIR fast-track funding for “Non-Activated Natural Killer...
Kytopen announces the first implementation of its GMP compliant Flowfect Tx™ cellular engineering...
Kytopen announces appointment of industry executive Kevin Gutshall as Chief Commercial Officer ...
Kytopen Announces Launch of Technology Access Program Supported by an Expanded Applications Team
Company Adds Proven Product Development and Commercial Leader as it Accelerates Launch of Flowfect®...
CAMBRIDGE, Mass. — July 11, 2023 — Kytopen, a leading biotechnology company specializing in...